Washington, DC 20006-5349
HELPLINE
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free…
In this episode of MesoTV, three patients, two with peritoneal mesothelioma and one with pleural mesothelioma, tell their stories of diagnosis, treatment, subsequent recurrence, and…
The Meso Foundation’s International Symposium on Malignant Mesothelioma is a unique conference that brings together the entire mesothelioma community. We invite patients, their families, caregivers,…
The field of integrative medicine combines conventional therapies with complementary ones in a thoughtful way to optimize outcomes and/or quality of life. Services provided under…
Data from a positive phase 2/3 clinical trial evaluating the effectiveness of a drug for mesothelioma was just published in the Journal of the American…
Hair loss, or alopecia, is often associated with cancer therapies and, in particular, with cytotoxic chemotherapy. While this side effect is most often temporary –…
Due to recent advances in cancer treatment, especially in the field of immunotherapy, chemotherapy treatment options for mesothelioma have taken a back seat. However, this…
A group of patients joins the patient panel at the 2023 International Symposium on Malignant Mesothelioma to discuss their experiences of diagnosis, finding an expert…
Radiation oncology is used as an adjuvant therapy to other modalities of treatment (and in some cases, it can even be used as a neoadjuvant therapy right before surgery). The goal of radiotherapy is to remove microscopic or stubborn disease left over from traditional systemic therapies and/or surgery. Sometimes radiotherapy…
This week, mesothelioma clinicians and researchers have come together in Lille, France, for the International Mesothelioma Interest Group‘s biannual meeting known as iMig to discuss…
